Macular Degeneration

no intervention

Vista Klinik

Correlation Between Visual Acuity Measurements, Quality of Life and Morphological Parameters in Wet AMD Patients

Correlation Between Reading Specific New Visual Acuity Measurement Methods, Patient Self-reported Quality of Life Assessments, Macular Morphological Parameters and Standardized Study Protocol ETDRS Visual Acuity in Wet AMD Patients

Pearson correlation between NEI VFQ-25 (National Eye Institute Visual Function Questionnaire) near visual acuity sub scale score (questions 5,6,7) (maximum score 1, minimum score 6, higher score indicates worse vision related to quality of life)

Pearson correlation between NEI VFQ-25 (National Eye Institute Visual Function Questionnaire) near visual acuity sub scale score (maximum score 1, minimum score 6, higher score indicates worse vision related to quality of life) and low luminance visual acuity and (min 0.3LogMAR, max -0.3LogMAR, higher score indicates indicates worse low luminance acuity)

Pearson correlation between NEI VFQ-25 (National Eye Institute Visual Function Questionnaire) near visual acuity sub scale score (maximum score 1, minimum score 6, higher score indicates worse vision related to quality of life) and contrast sensitivity score(min 0.00,max 2.25, higher score indicates highest/best contrast sensitivity)

Pearson correlation between NEI VFQ-25 (National Eye Institute Visual Function Questionnaire) near visual acuity sub scale score (maximum score 1, minimum score 6, higher score indicates worse vision related to quality of life) and ETDRS 4m distance visual acuity score (min 0.3LogMAR, max -0.3LogMAR, higher score indicates indicates worse ETDRS visual acuity)

Pearson correlation between NEI VFQ-25 (National Eye Institute Visual Function Questionnaire) near visual acuity sub scale score (maximum score 1, minimum score 6, higher score indicates worse vision related to quality of life)

no IPD, this is a not interventional study

Dr. med. Katja Hatz

Head of Medical Retina Department

Double-blind placebo controlled oral challenge 5-50-200-1000 mg peanut or hazelnut protein, or placebo administered with 30 min intervals and 2 hour-follow-up after the last dose.

Patients who have moderate to severe immediate allergic reaction at peanut challenge and who enter the oral desensitization program receive peanut protein daily, from 0,1 mg to 800 mg peanut protein, maintenance dose 800 mg.

Nut Allergy

Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding

Nut challenge

Dried banana mixed with oat yoghurt or chocolate pudding

Nut challenge: Placebo

Roasted peanut powder mixed with milk- and soy-free margarine

Nut oral desensitization

Helsinki University Central Hospital, Skin and Allergy Hospital

Nut Allergy Study: Double-blind Challenge and Oral Desensitization

Nut Allergy Study: Improving Diagnosis And Treatment Of Nut Allergy

Change from baseline in the amount of nut (mg) tolerated in a double-blind placebo-controlled oral challenge at 1 month after the 6-month oral desensitization therapy.

Change from baseline in Quality of life questionnaire square before and after the oral desensitization therapy

Change from baseline in bronchial hyperreactivity in metacholine challenge and in eosinophilic airway inflammation measured by multiple channel exhaled nitric oxid

Number of participants with adverse events as a measure of safety and tolerability

corylus avellana/upala

Correlation Between Visual Acuity Measurements, Quality of Life and Morphological Parameters in Wet AMD Patients

Nut Allergy Study: Double-blind Challenge and Oral Desensitization

Najkompletnija baza ljekovitog bilja potpomognuta znanošću